Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Annual Conference on Retroviruses and Opportunistic Infections (CROI)

Select coverage from The Annual Conference on Retroviruses and Opportunistic Infections (CROI) is included below:

Direct-Acting Antiviral Combo Yields High Rates of SVR in Patients with Previous Virologic Failure
The combination of direct-acting antiviral agents glecaprevir/pibrentasvir (G/P), sofosbuvir, and ribavirin is now approved for new patient populations.
 
Identifying Variables Predictive of HIV Acquisition in Electronic Health Records
Douglas Krakower, MD, discusses which variables in electronic health records could be used to identify candidates for pre-exposure prophylaxis.
Low Dose Hydrocortisone Found to Enhance Cognitive Function in Women with HIV
Findings from a recent study find enduring effects of LDH on learning and memory, suggesting potential clinical utility in women with HIV.
Importance of Studying Ways to Improve Cognition In Women With HIV
Leah H. Rubin, PhD, MPH, MA, discusses the importance of finding ways to improve cognitive function in women who are living with HIV.
Electronic Health Record Data Expanding in Use to Identify Those at Risk of Diseases
Douglas Krakower, MD, explains how electronic health records have expanded in use in order to identify people at risk for diseases who could benefit from preventive interventions.
Shorter Duration Tuberculosis Prevention Option Available for People Living With HIV
A new study finds that a 1-month course of antibiotics is as safe & effective as the commonly recommended 9-month course in preventing tuberculosis in those with HIV.
Dolutegravir with Darunavir/Cobicistat Safe to Prescribe in Treatment of HIV, Study Suggests
A new study suggests that an antiretroviral combination of dolutegravir with darunavir/cobicistat can be prescribed safely in the treatment of HIV-1.
Improving Access to Patient Care & Time to Viral Suppression Using HIV Rapid Entry Programs
Implementation of a rapid entry program decreased time to first provider appointment, time to initiation of ART, and time to viral suppression in the Southern United States.
FEATURED
Big advances in treatment can